Loading
A phase 2/3 trial of Trastuzumab, Toripalimab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., active and no longer recruiting.
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer is a phase 2/3 interventional study registered as NCT05980481 by RemeGen Co., Ltd., with 201 participants enrolled, started 2023-08-04 and due to reach its primary completion in 2025-07-10. Interventions recorded: RC48-ADC（2.5mg/kg）, Trastuzumab, Toripalimab, Oxaliplatin（130mg/m2 ）, Capecitabine（1000mg/m2） and RC48-ADC（2.0mg/kg）.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Oxaliplatin, Trastuzumab, Capecitabine and the tag pipeline.
Shares RemeGen, Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Toripalimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/